Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Flannelly Barry P | EVP & General Manager US | Apr 08 | Option Exercise | 70.48 | 41,864 | 2,950,628 | 88,640 | Apr 12 04:10 PM | Flannelly Barry P | EVP & General Manager US | Apr 08 | Sale | 83.49 | 43,993 | 3,672,887 | 65,163 | Apr 12 04:10 PM | BAKER BROS. ADVISORS LP | Director | Mar 10 | Buy | 73.13 | 218,563 | 15,982,720 | 33,419,055 | Mar 10 06:02 PM | BAKER BROS. ADVISORS LP | Director | Mar 09 | Buy | 71.72 | 70,517 | 5,057,550 | 33,217,136 | Mar 10 06:02 PM | BAKER BROS. ADVISORS LP | Director | Mar 08 | Option Exercise | 22.05 | 40,000 | 882,000 | 33,059,604 | Mar 10 06:02 PM | BAKER BROS. ADVISORS LP | Director | Mar 08 | Buy | 70.67 | 100,000 | 7,067,500 | 33,151,989 | Mar 10 06:02 PM | BAKER BROS. ADVISORS LP | Director | Feb 22 | Buy | 68.07 | 99,800 | 6,793,536 | 33,039,604 | Feb 22 05:45 PM | BAKER BROS. ADVISORS LP | Director | Feb 18 | Buy | 68.38 | 133,032 | 9,096,550 | 32,947,370 | Feb 22 05:45 PM | BAKER BROS. ADVISORS LP | Director | Feb 17 | Buy | 67.74 | 292,972 | 19,844,805 | 32,824,461 | Feb 22 05:45 PM | Dickinson Jonathan Elliott | EVP, General Manager, Europe | Jan 31 | Sale | 74.19 | 7,375 | 547,151 | 30,214 | Feb 02 04:25 PM | SWAIN PAULA J | EVP, Human Resources | Jan 07 | Option Exercise | 73.21 | 10,870 | 795,793 | 83,241 | Jan 11 04:18 PM | SWAIN PAULA J | EVP, Human Resources | Jan 07 | Sale | 73.31 | 10,870 | 796,880 | 72,371 | Jan 11 04:18 PM | SWAIN PAULA J | EVP, Human Resources | Jan 04 | Option Exercise | 73.21 | 9,319 | 682,244 | 81,690 | Jan 05 04:25 PM | SWAIN PAULA J | EVP, Human Resources | Jan 04 | Sale | 73.46 | 9,319 | 684,574 | 72,371 | Jan 05 04:25 PM | Trower Paul | Principal Accounting Officer | Jan 03 | Option Exercise | 73.21 | 8,214 | 601,347 | 39,086 | Jan 05 04:40 PM | Trower Paul | Principal Accounting Officer | Jan 03 | Sale | 73.31 | 8,214 | 602,168 | 32,268 | Jan 05 04:40 PM | DIXON WENDY L | Director | Dec 23 | Option Exercise | 73.25 | 20,000 | 1,465,000 | 37,259 | Dec 27 04:11 PM | DIXON WENDY L | Director | Dec 23 | Sale | 22.05 | 20,000 | 441,000 | 17,259 | Dec 27 04:11 PM | BAKER BROS. ADVISORS LP | Director | Dec 17 | Buy | 72.80 | 1,075,872 | 78,322,148 | 30,932,696 | Dec 17 06:30 PM | BAKER BROS. ADVISORS LP | Director | Dec 16 | Buy | 71.96 | 169,315 | 12,184,411 | 29,856,824 | Dec 17 06:30 PM | BAKER BROS. ADVISORS LP | Director | Dec 15 | Buy | 71.51 | 350,332 | 25,052,340 | 29,687,509 | Dec 17 06:30 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Oct 01 | Sale | 68.67 | 389 | 26,713 | 31,263 | Oct 04 04:41 PM | Pasquale Maria E | EVP & General Counsel | Sep 24 | Option Exercise | 65.36 | 382 | 24,968 | 36,187 | Sep 28 08:18 AM | SWAIN PAULA J | EVP, Human Resources | Sep 20 | Option Exercise | 73.21 | 1,356 | 99,273 | 60,959 | Sep 21 04:09 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Sep 01 | Sale | 76.71 | 388 | 29,763 | 31,652 | Sep 03 07:40 AM | Dhanak Dashyant | EVP & Chief Scientific Officer | Aug 02 | Sale | 77.49 | 389 | 30,144 | 32,040 | Aug 04 04:16 PM | Iyengar Vijay K | EVP GPS, BD, & Licensing | Jul 29 | Sale | 78.29 | 4,911 | 384,482 | 27,005 | Aug 02 04:14 PM | Wenqing Yao | EVP, Head of Discovery Chem | Jun 29 | Sale | 85.37 | 27,194 | 2,321,552 | 94,080 | Jun 30 04:11 PM | Pasquale Maria E | EVP & General Counsel | Jun 18 | Option Exercise | 65.36 | 255 | 16,667 | 30,193 | Jun 22 04:04 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Jun 10 | Option Exercise | 65.42 | 3,845 | 251,540 | 30,390 | Jun 14 04:28 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Jun 10 | Sale | 87.00 | 3,845 | 334,515 | 26,545 | Jun 14 04:28 PM | Dhanak Dashyant | EVP & Chief Scientific Officer | Jun 01 | Sale | 84.13 | 395 | 33,231 | 26,545 | Jun 03 04:42 PM |
|